CAR-T Cell Funding Market Size, Share, By Therapy Type (Tisagenlecleucel-T, Axicabtagene ciloleucel, Brexucabtagene autoleucel, Lisocabtagene maraleucel, Idecabtagene vicleucel, and Ciltacabtagene autoleucel), By Investment Trend (Early-Stage investment, Late-Stage investment, and Strategic investment), By Funding Source Type (Venture Capital, Public Funding, Corporate Investments, and Others), By Application (Acute Lymphoblastic Leukemia (ALL), Ovarian Cancer, Acute Myeloid Leukemia (AML), Rheumatoid Arthritis (RA), and Others), By End-User (Pharmaceutical Companies, Research and Academic Institutions, Contract Research Organizations (CROs), Outpatient Surgery Centers, and Others), and Region (North America, Europe, Asia Pacific, Middle East and Africa, and South America) - Trends, Analysis and Forecast till 2034

Report Code: PMI558024 | Publish Date: August 2024 | No. of Pages: 195

Car T Cell Funding Market Companies

  • Gilead Sciences, Inc.
  • Novartis AG
  • Bristol-Myers Squibb Company
  • Johnson & Johnson
  • Bluebird Bio, Inc.
  • Kite Pharma, Inc.
  • Celgene Corporation
  • AbbVie Inc.
  • Adaptimmune Therapeutics plc.
  • Tessa Therapeutics
  • Celyad Oncology SA
  • Autolus Therapeutics plc.
  • Legend Biotech Corporation
  • Sorrento Therapeutics, Inc.
  • Iovance Biotherapeutics, Inc.

Recent News:

  • In July 2024, The Multiple Myeloma Research Foundation (MMRF) has invested $1 million in Dynamic Cell Therapies (DCT)'s cutting-edge CAR T-cell technology in an effort to improve the treatment of multiple myeloma through its Myeloma Investment Fund. Backed by this investment, DCT remains on track to move a new CAR T-cell therapy into clinical testing in people with relapsed and refractory multiple myeloma over the next few years.